New indication for Merck & Co’s Keytruda

FDA approved the use of Keytruda, a PD-1 inhibitor, in Hodgkin lymphoma. Thus, the cancer drug developed by Merck & Co. becomes the first PD-1 inhibitor approved for the treatment of liquid cancers. The approval was supported by results from the Keynote-087 clinical trial, conducted on 210 patients, that showed 69% of these patients positively responded to treatment (complete response rate of 22% and partial response rate of 47%). Hodgkin lymphoma is a relatively rare cancer type, with 7,500-8,000 annual cases, originating in the lymphatic system. (Source Merck & Co.)